Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a post by JAMA Oncology on LinkedIn, adding:
“What does chemotherapy add to immune checkpoint inhibitors in patients with advanced NSCLC and high PD-L1 expression (50% or greater)?
In our meta-analysis of 24 trials including reconstructed individual patient data, we observed a meaningful improvement in both median PFS (11.3 vs 6.8 months, HR 0.67) and OS (29.2 vs 19.8 months, HR 0.74) with chemo-immunotherapy versus immune checkpoint inhibitors monotherapy.
This effort was possible thanks to Biagio Ricciuti as well as extraordinary international collaborators.”
Quoting JAMA Oncology‘s post:
“In a systematic review and meta-analysis of 24 phase 3 randomized clinical trials including over 5500 patients with untreated advanced non–small cell lung cancer (NSCLC) and high programmed cell death ligand 1 (PDL1) expression (≥50%), first-line chemoimmunotherapy was associated with significantly longer overall survival and progression-free survival compared with programmed cell death 1 protein or ligand 1 (PD-[L]1) inhibitor monotherapy.
These benefits persisted across multiple analytic methods, including reconstructed individual patient data and sensitivity analyses with long-term follow-up. Results were consistent regardless of analytic approach, suggesting a robust advantage for chemoimmunotherapy in this population. However, treatment-related adverse events and discontinuation rates were higher with chemoimmunotherapy.
These findings suggest that first-line combination chemoimmunotherapy may provide greater clinical benefit than Immunotherapy Monotherapy for patients with high PDL1 advanced NSCLC, pending results of direct comparative trials.”
Title: PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
Authors: Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, Sara Stumpo, Andrea De Giglio, Federica Pecci, Joao V. Alessi, Xinan Wang, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Maria A. Pantaleo, Andrea Arfè, Hossein Borghaei, Marina C. Garassino, Federico Cappuzzo, Andrea Ardizzoni, Mark M. Awad, Biagio Ricciuti
Read The Full Article
Other articles about Immunotherapy on OncoDaily.